Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lichuan Liu

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349Zhonghua Pei, Elizabeth Blackwood, Lichuan Liu, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834Wendy B Young, James Barbosa, Peter Blomgren, et al.
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
JCI Insight|April 14, 2017
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritisArna Katewa, Yugang Wang, Jason A Hackney, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349Zhonghua Pei, Elizabeth Blackwood, Lichuan Liu, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834Wendy B Young, James Barbosa, Peter Blomgren, et al.
Journal of Medicinal Chemistry|May 27, 2016
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical DevelopmentJames F Blake, Michael Burkard, Jocelyn Chan, et al.
JCI Insight|April 14, 2017
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritisArna Katewa, Yugang Wang, Jason A Hackney, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Pageof 6